Dupilumab efficacy across serum <scp>IgE</scp> and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis

Published:2024-06-08 Issue: Volume: Page:
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Bachert Claus¹²^ORCID,Gevaert Philippe³^ORCID,Lipworth Brian⁴,Mustafa Syed Shahzad⁵^ORCID,Lane Andrew P.⁶^ORCID,Mullol Joaquim⁷,Rowe Paul⁸,Deniz Yamo⁹,Kamat Siddhesh⁹,Khan Asif H.⁸^ORCID,Jacob‐Nara Juby⁸,Siddiqui Shahid⁹,Ruddy Marcella⁹,Laws Elizabeth⁸,Msihid Jérôme¹⁰,Harel Sivan⁹,Jagerschmidt Alexandre¹¹,Amin Nikhil⁹,Mannent Leda¹⁰,Rout Raj¹²

Affiliation:

1. University Hospital of Münster Münster Germany

2. Sun Yat‐sen University, The First Affiliated Hospital Guangzhou China

3. Ghent University Ghent Belgium

4. University of Dundee Dundee UK

5. Rochester Regional Health Rochester New York USA

6. Johns Hopkins School of Medicine Baltimore Maryland USA

7. Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, CIBERES Barcelona Catalonia Spain

8. Sanofi Bridgewater New Jersey USA

9. Regeneron Pharmaceuticals Tarrytown New York USA

10. Sanofi Gentilly France

11. Sanofi Chilly‐Mazarin France

12. Sanofi Reading UK

Funder

Sanofi

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.16189

Reference6 articles.

1. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis

2. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

3. Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps

4. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results

5. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3